1.
吉西他滨联合铂类方案的临床研究
Studies of gemcitabine-platinum combined chemotherapy
| Author/reference | Weeks | Schedule and dose | Hematologic toxicity | Median suvival (month) |
Response rate (%) |
| G: gemcitabine; C: cisplatin. | |||||
| Manegold, et al[4] (2000) | 3 | G (1, 000-1, 250 mg/m2) d1, 8 C (75 mg/m2) d1 |
- | 8.4-15.4 | 30-59 |
| Sandler, et al[5] (2000) | 4 | G (1, 000 mg/m2) d1, 8, 15 C (100 mg/m2) d1 |
Neutropaenia at grade 4 (35.3%) Thrombocytopaenia at grade 4 (25.4%) |
9.1 | 30.4 |
| Scagliotti, et al[17](2002) | 3 | G (1, 250 mg/m2) d1, 8 C (75 mg/m2), d2 |
Neutropaenia (17%) Thrombocytopaenia (16%) |
9.8 | 30 |
| Jassem, et al [18] (2002) | 4 | G (1, 000 mg/m2) d1, 8, 15 C (100 mg/m2) d2 |
Anemia at grade 3/4 (30%) Neutropaenia at grade 3/4 (58%) Thrombocytopaenia at grade 3/4 (65%) |
11.0 | 41 |
| Gaafar, et al[19] (2004) | 3/4 | G (1, 000-2, 500 mg/m2) d1, 8, (15) C (80-100 mg/m2), d1/15 |
Anemia at grade 3/4 (18.6%) Neutropaenia at grade 3/4 (32.6%) Thrombocytopaenia at grade 3/4 (20.4%) |
9 | 41.7 |